london euretina
retina race

VEGF-A level in the lacrimal fluid in patients with diabetic retinopathy of varying severity

Session Details

Session Title: Vascular Diseases and Diabetic Retinopathy

Session Date/Time: Friday 18/09/2015 | 11:00-12:30

Paper Time: 12:12

Venue: Calliope

First Author: : Y.Borzilova RUSSIAN FEDERATION

Co Author(s): :                  

Abstract Details

PURPOSE:Pathological angiogenesis and the development of macular edema in diabetic retinopathy significantly depend on the level of vascular endothelial growth factor (VEGF-A). The definition of this indicator for evaluating the effectiveness of various treatment methods, and non-invasive way, is a very urgent task.

Setting:

To determine the VEGF-A level in the lacrimal fluid of patients with different stages of DR.

Methods:

The lacrimal fluid of 56 people (95 eyes) with diabetes mellitus type 2, of which 11 persons (11 eyes) with no DR and 45 patients (84 eyes) suffering from DR of varying degrees of severity. The VEGF-A level in stimulated lacrimal fluid was determined by enzyme immunoassay using the test systems “Human VEGF-A Platinum BMS277/2* RUO ELISA Kit” (BioSource International Inc., USA).

Results:

VEGF-A was found in all patients. VEGF-A in diabetes without DR was 1425,5±257,3 pg / ml, with nonproliferative DR of 1-2 stages significantly increased up to 2002,4±134,7 pg / ml, with preproliferative and proliferative DR (PDR) of 1 stage remained at the same level - 2204,4±140,5 and 1957,5 pg / ml, respectively. In the 2-3 stages of PDR DR, it considerably increased to 2527,5 pg / ml, while in the terminal conditions, especially in the presence of traction retinal detachment it decreased sharply, reaching a value of 534,7 pg / ml.

Conclusions:

The study of VEGF-A in stimulated lacrimal fluid by enzyme immunoassay revealed differences in its level at different stages of diabetic retinopathy. Further investigations are needed with more volume of clinical material, as well as to determine the possibility of using VEGF-A testing in tear for / effectiveness evaluation of various DR treatment methods.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy